Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy. BMC Research Notes , 2024; 17 (1) DOI: 10.1186/s13104-024-07016-y Cite This Page : ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma. The FDA granted fast track designation to amezalpat (TPST-1120) for the potential ...

Hepatocellular carcinoma (HCC) is a lethal malignancy with a lack of effective treatments particularly for the disease at an advanced stage. Even though immune checkpoint inhibitors (ICIs) have made ...

Objective Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by ...

You will be able to get a quick price and instant permission to reuse the content in many different ways. This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), ...

This highlights a potential clinically translational impact of HCC genetic polymorphisms and different etiologies on treatment outcome. Specifically, we identify that the basal cellular CYP3A4 ...

Background and Aim It has been reported about poor prognosis in patients with advanced hepatocellular carcinoma (HCC) refractory to hepatic arterial infusion chemotherapy (HAIC). We assessed the ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

chemotherapy with a reservoir and non-treatment for HCC were similar in both groups. No statistical difference was observed regarding the types of treatment between both groups. Of the 36 patients ...

End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI). This is an ASCO Meeting Abstract from the 2025 ...